CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma

Today’s Highlights January 28, 2021

CASI Pharmaceuticals Partner, BioInvent International, Announced Positive Interim Results for NHL
CASI Pharmaceuticals (CASI) partner BioInvent International (This content is for paid subscribers.

Please click here to subscribe or here to log in.

Today’s Highlights
BioInvent International AB (BINV), CASI Pharmaceuticals Inc (CASI)
January 28, 2021

Tweet Pin It

Other Articles

Novo Nordisk: European Regulatory Authority Adopts Positive Opinion for an Update of Ozempic® Label to Reflect Risk Reduction of Kidney Disease-Related Events

December 12, 2024 0

At ASH 2024, Gilead Sciences’ Kite’s Yescarta® Shows Its CAR T-Cell Therapy Uniquely Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

December 10, 2024 0

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

December 9, 2024 0

Why Keros Therapeutics is Getting $200 Million Upfront Payment and Possibly Future Payments from Takeda That Could Exceed $1.1 Billion and More

December 3, 2024 0

Search ProhostBiotech

Popular Links
Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Neurocrine Biosciences (NBIX) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)

Recent

ProhostBiotech Archive
ProhostBiotech Archive
Sign Up for Weekly Emails
First Name

Last Name

Email address:

Prohost Biotech – Exclusive Biotech Research Copyright © 2024.
© 2014 Prohost Biotech. All rights reserved.
Privacy Policy | Cancellation Policy | Forward Looking Statement

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Accept Privacy policy

Exclusive Market Insight

& Scientific analysis

CASI Partner, BioInvent, Announced the Combination of Rituximab with BI-1206 restored riruximab’s Capability to Treat Indolent Relapsed or Refractory B-cell non-Hodgkin’s Lymphoma